Inhibikase Therapeutics (IKT) announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., former CMO of Arena Pharmaceuticals and CEO of CorHepta Pharmaceuticals, has been appointed as President and Head of Research & Development. Additionally, CorHepta co-founder and former Head of Research at Arena Pharmaceuticals, John Adams, Ph.D. has been appointed Chief Scientific Officer. Additionally, Vince Aurentz will join Inhibikase Board of Directors He served as Executive Vice President and Chief Business Officer at Arena Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT: